Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $376,236.90 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Supernus Pharmaceuticals Stock Down 1.3 %

Supernus Pharmaceuticals stock traded down $0.52 during mid-day trading on Wednesday, hitting $39.48. 310,305 shares of the company’s stock were exchanged, compared to its average volume of 362,931. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The firm has a market capitalization of $2.18 billion, a P/E ratio of 36.90 and a beta of 0.90. The company’s 50 day simple moving average is $37.24 and its 200-day simple moving average is $34.66.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the previous year, the business posted ($0.29) EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on SUPN shares. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They set an “overweight” rating and a $57.00 target price on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC lifted its position in Supernus Pharmaceuticals by 395.1% in the 2nd quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock valued at $4,316,000 after acquiring an additional 128,743 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Supernus Pharmaceuticals by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock valued at $710,000 after purchasing an additional 1,870 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $1,070,000. GAMMA Investing LLC grew its holdings in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares in the last quarter. Finally, Exchange Traded Concepts LLC acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at approximately $672,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.